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Abstract 
Chronic cerebral hypoperfusion (CCH) evokes mild cognitive impairment (MCI) and 
contributes to the progression of vascular dementia and Alzheimer’s disease (AD). How CCH 
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induces these neurodegenerative processes that may spread along the synaptic network and 
whether they are detectable at the synaptic proteome level of the cerebral cortex remains to be 
established.  
In the present study, we report the synaptic protein changes in the cerebral cortex after 
stepwise bilateral common carotid artery occlusion (BCCAO) induced CCH in the rat. The 
occlusions were confirmed with Magnetic Resonance Angiography 5 weeks after the surgery. 
Synaptosome fractions were prepared using sucrose gradient centrifugation from cerebral 
cortex dissected 7 weeks after the occlusion. The synaptic protein differences between the 
sham operated and CCH groups were analysed with label free nanoUHPLC-MS/MS.  
We identified 46 proteins showing altered abundance due to CCH. In particular, 
synaptic protein and lipid metabolism, as well as GABA shunt related proteins showed 
increased while neurotransmission and synaptic assembly related proteins showed decreased 
protein level changes in CCH rats. Protein network analysis of CCH induced protein 
alterations suggested the importance of increased synaptic apolipoprotein E (APOE) level as a 
consequence of CCH. Therefore, the change in APOE level was confirmed with Western 
blotting. The identified synaptic protein changes would precede the onset of dementia-like 
symptoms in the CCH model suggesting their importance in the development of vascular 
dementia. 
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Introduction 
Chronic cerebral hypoperfusion (CCH) is relatively common in the elderly and it is a 
major contributor to cerebrovascular dementia (Cankurtaran et al., 2008, Valerio Romanini et 
al., 2013) and also an important risk factor for Alzheimer’s disease (AD) (Sato and Morishita, 
2013). However, the molecular background how CCH causes cognitive impairment and how 
it contributes to Alzheimer’s pathogenesis is poorly understood, even though a deeper 
understanding of the molecular process would be essential for developing new therapeutic 
strategies to prevent the progression of CCH towards AD. 
CCH can be detected in mild cognitive impairment prior to dementia using different 
imaging techniques (Borroni et al., 2006). CCH causes capillary degeneration, which reduces 
the diffusion of nutrition and oxygen supply to brain cells resulting in the degeneration of the 
nerve tissue. The onset of CCH is in the associative cortical areas, then it spreads throughout 
the brain via the neuronal network, affecting large parietal and temporal cortical areas (Zadori 
et al., 2007). Synapse loss is an early feature of AD which correlates with the severity of 
dementia (Shankar and Walsh, 2009). 
Bilateral common carotid artery occlusion (BCCAO) induced CCH is a widely used 
model of vascular dementia (Farkas et al., 2007, Jing et al., 2015). For better survival rate and 
to avoid the acute ischemic stroke, we used a CCH model where BCCAO was induced with 
one-week interval between occlusions of the left and right common carotid arteries (Cechetti 
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et al., 2010), which leads to a more gradual development of CCH in the brain (Jing et al., 
2015). The rat is a frequently used species of this model due to its good recovery rate from 
surgery, the good reproducibility, and because the complete circle of Willis allows permanent 
carotid occlusion during a period of reduced blood flow after the onset of BCCAO. This 
animal model shows learning and memory impairments resembling those found in AD and 
vascular dementia, accompanied by neuronal degeneration, long-lasting white matter lesion, 
microglial activation, astrocytosis and microvascular abnormalities (de la Torre et al., 2003, 
Farkas et al., 2007). White matter damage is detectable with diffusion tensor imaging (DTI) at 
the early stages of brain injury following CCH (Wang et al., 2015). In addition, cerebral 
hypoperfusion accelerates cerebral amyloid angiopathy (Okamoto et al., 2012), enhances tau 
hyperphosphorylation, upregulates β-amyloid precursor protein cleavage enzyme 1 (BACE1) 
and β-amyloid level in the brain (Zhiyou et al., 2009), the main neuropathological hallmarks 
of AD. 
Although the underlying pathophysiological mechanisms and their consequences have 
been widely studied in the CCH model, unbiased proteomic studies are scarce and the 
molecular changes in CCH-affected brain are not well understood. Because CCH induced 
neurodegeneration spreads along the neuronal networks, the aim of the present study was to 
describe the effect of CCH on synaptic proteome of the rat cerebral cortex focusing on its 
possible role in the progression of AD. 
 
Methods 
Animals 
The care and experimentation of all animals conformed to the Hungarian Act of 
Animal Care and Experimentation (1998, XXVIII) and to the guidelines of the European 
Communities Council Directive, 86/609/EEC as well as with local regulations for the care and 
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use of animals for research. Rats were kept under standard laboratory conditions (12-hour 
light/dark cycle, lights on at 08.00 a.m. and off at 08.00 p.m.) with free access to food and 
water. Three months old male Harlan	Wistar rats (weights 310-390 g at the beginning of the 
experiments)	were subjected to stepwise complete bilateral occlusion of the common carotid 
arteries (n=6). Sham operated rats without artery occlusion served as control group (n=6). For 
better survival rate and to avoid the ischemic lesions of the brain, the two common arteries 
were occluded with one week delay (stepwise BCCAO) and the sham operated animals were 
also operated with this schedule. 
 
Stepwise occlusion of common carotid arteries  
Rats were anesthetized with isoflurane (1.5-2 % in air); and a ventral midline incision 
was made on the neck. Common carotid arteries were exposed and gently separated from the 
vagus nerve and the left carotid artery was occluded in the first step by three ligatures (2-0). 
One week later a new incision was made and the right carotid was occluded as well in the 
second step. The sham operated animals were also operated with this schedule, the same 
thread (2-0) was placed around the vessels without ligatures. After the procedure, rats were 
put back to their home cages and allowed to recover.  
 
Magnetic Resonance Angiography 
The occlusions were confirmed with Magnetic Resonance Angiography (MRA). 5 
weeks after the second occlusion anaesthetized animals (isoflurane in air 1-1.5 %) were 
scanned in a 9.4 T MRI system (Varian, Medical Systems Inc., Palo Alto, CA) with a free 
bore of 210 mm, containing a 120 mm inner size gradient coil. 3D time-of-flight (TOF) 
angiography (3D gradient echo) was performed with TR/TE = 30/2.8 msec, resolution = 0.42 
x 0.42 x 0.46 mm. 
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Dissection of cerebral cortical samples  
The Wistar rats from both groups (n=6-6) were anesthetized with isoflurane (1-1.5 % 
in air) then decapitated and the brains were removed rapidly. The brains were washed in 
artificial cerebral spinal fluid (ACSF), the cerebral cortices were dissected and the tissue 
samples were immediately frozen on dry ice and stored at -80 oC until further studies. 
 
Isolation of synaptosomes from rat cerebral cortical samples 
Synaptosomes were prepared by the method of Hahn et al. with minor modifications 
(Hahn et al., 2009). Briefly, the cerebral cortical tissue was homogenized using a Dounce type 
glass homogenizer (Small Clearance, Kontes Glass Co.) with 40 strokes in 1 ml of 
homogenization buffer (320 mM sucrose, 0.1 mM CaCl2, 1 mM MgCl2) supplemented with 
protease and phosphatase inhibitor cocktails (Sigma-Aldrich, St.Louis, MO, USA). To avoid 
postmortem degradation all steps were performed on ice in a cold room. The homogenate was 
adjusted to 1.25 M sucrose and 0.1 mM CaCl2 to a total volume of 5 ml and was transferred to 
a centrifuge tube. 5 ml of 1 M sucrose solution was overlaid on it and centrifuged at 100 000 
× g for 3 hours in an SW-40 rotor. The band at the interface was collected with a needle as the 
synaptosome fraction. To reduce the sucrose content of the fraction the sample was diluted 
with 5 x 0.1 mM CaCl2 and centrifuged at 15 000 × g for 20 min. The pellet was precipitated 
with ice cold acetone overnight. On the next day the sample was spinned down, the acetone 
was removed and the pellet was allowed to dry. 
 
Electron microscopy validation of synaptosome samples 
For the electron microscopic validation, synaptosome fractions were fixed with 2 % 
formaldehyde (freshly depolymerized from paraformaldehyde) and 0.5 % glutaraldehyde in 
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0.1 M Na-cacodylate for 30 min at room temperature.	The samples were postfixed in 0.5 % 
osmium tetroxide and 0.75 % potassium hexacyano-ferrate for 45 min, dehydrated and 
embedded in LR White resin according to the manufacturer's instructions. Ultrathin sections 
(70 nm) were examined in JEOL JEM 1011 electron microscope operating at 60 kV. Images 
were taken with an Olympus Morada 11-megapixel camera and iTEM software (Olympus).  
 
Processing of synaptosomes for proteome analysis  
The precipitated samples were taken up in lysis buffer (7 M urea, 2 M thiourea, 20 
mM Tris, 5 mM Mg(Ac)2, 50 mM DTT) and were sonicated on ice until completely 
dissolved. The concentration was determined using the 2D Quant Kit (GE Healthcare, Little 
Chalfont, UK). The proteins were digested using the filter aided sample preparation method 
published by Wisniewski et al. with minor modifications (Wisniewski et al., 2009). Briefly, 
150 µg of the sample was diluted to a volume of 200 µl with urea buffer (8 M urea, 100 mM 
Tris-HCl pH 8.5) transferred to a Microcon YM-30 filter device (Merck, Germany) and 
spinned down at 14000 × g for 15 min at room temperature. Then 200 µl urea buffer was 
added to the sample and spinned down again. To carbamidomethylate the proteins, 100 µl of 
IAA solution (50 mM iodoacetamide, 8 M urea, 100 mM Tris-HCl pH 8.5) was pipetted onto 
the filter and mixed at 450 rpm at room temperature for 3 min in a thermo-mixer. Then 
incubated for 45 min at RT in dark without mixing and the sample was centrifuged for 10 min 
at the end. 100 µl of urea solution was added to the sample, spinned down for 15 min, and this 
step was repeated twice. Later, 100 µl of 50 mM NH4HCO3 was added and the sample was 
centrifuged for 10 min, and this step was also repeated twice. The proteins were recovered 
from the filter by a reverse spin of 1500 × g for 3 min and 100 µl of digestion solution (0.1 % 
RapiGest, 50 mM NH4HCO3) and trypsin (Sequencing grade modified, Promega, Madison, 
WI, USA) were added in a 1:50 ratio. The sample was digested overnight at 37 oC. The 
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following day the reaction was stopped by adding 4 µl of formic acid and the sample was 
desalted on a Pierce C-18 spin column (Thermo Scientific, Sunnyvale, CA, USA) according 
to the instruction of the supplier and dried in a speed-vac. 
 
Protein identification by nanoUHPLC-MS/MS  
Liquid chromatography-mass spectrometry was performed using a Maxis II ETD 
QqTOF (Bruker Daltonics, Bremen, Germany) coupled to an Ultimate 3000 nanoRSLC 
system (Dionex, Sunnyvale, CA, USA) under the control of Hystar v.3.2 (Bruker Daltonics, 
Bremen, Germany). Samples were dissolved in 40 µl of 2 % Acetonitril and 0.1 % formic 
acid in water, out of which 5 µl were injected onto an Acclaim PepMap100 C-18 trap column 
(100 µm x 20 mm, Thermo Scientific, Sunnyvale, CA, USA). Sample desalting and 
preconcentration were performed with 0.1 % trifluoracetic acid for 8 min with a flow rate of 5 
µl/min. Peptides were separated on an ACQUITY UPLC M-Class Peptide BEH C18 column 
(130 Å, 1.7 µm, 75 µm x 250 mm, Waters, Milford, MA, USA) at 48 oC using a flow rate of 
300 nl/min. HPLC solvents were as follows: solvent A consisted of 0.1 % formic acid in 
water and solvent B consisted of 0.1 % formic acid in acetonitrile. The gradient was as 
follows: 4% B from 0 to 11 min, followed by a 120 min gradient to 50 % B, then the 
concentration of the solvent B was elevated to 90 % in 1 min and kept there for 10 min. After 
each sample a blank was ran to avoid carryover. Sample ionization was achieved in the 
positive electrospray ionization mode via a CaptiveSpray nanoBooster ion source. The 
capillary voltage was set to 1300 V, the nanoBooster pressure was 0.2 Bar, the drying gas was 
heated to 150 oC and the flow rate was 3 l/min. External mass calibration was done using the 
low concentration tuning mix from Agilent technologies via direct infusion. Internal mass 
calibration was performed via lock mass for each run using sodium formate. The ion transfer 
parameters were set as follows: prepulse storage 10 µs, collision transfer 10 µs, quadrupole 
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ion energy 5 eV, Funnel 1 RF 400 Vpp, Multipole RF 400 Vpp. The collision RF was set to 
1200 Vpp and the ion transfer time was 120 µs. The MS spectra were recorded with a fix 
cycle time of 2.5 sec over the mass range of m/z 150-2200 at 3 Hz with a minimal precursor 
mass of 322 m/z. The CID was performed at 16 Hz for abundant precursors and at 4 Hz for 
ones of low abundance. Singly charged peptides were excluded from the analysis, only 
multiple charged peptides were chosen for fragmentation. The collision energy for precursor 
signals was set automatically followed by the manufacturer’s recommendations based on the 
isolation m/z, isolation mass range width and charge state of the ion. An active exclusion of 2 
min after 1 spectrum was used except if the intensity of the precursor was elevated threefold. 
For protein content analysis, raw data were recalibrated using the Compass DataAnalysis 
software 4.3 (Bruker Daltonics, Bremen, Germany). The samples were matched with the 
Rattus norvegicus SwissProt database using the Mascot server v.2.5 (Matrix Science, London, 
UK). The parameters for the Mascot search were set as follows: trypsin as the enzyme, and 
maximum 2 missed cleavages were allowed. Cysteine carbamidomethylation and methionin 
oxidation were used as fixed and variable modifications, respectively. Precursor mass 
tolerance was set to 7 ppm, the MS/MS mass tolerance was 0.05 Da. Decoy database was 
generated by Mascot and the false discovery rate was less than 1 % in each search result. 
Proteins with a minimum of two identified, unique peptides were accepted. Label free 
quantification was performed using MaxQuant software version 1.5.3.30. LC-MS/MS runs 
were aligned using the “match between runs” feature (match time window 0.8 min, alignment 
time window 15 min). The following requirements were set: minimum peptide ratio count 2 
and „unique + razor” peptide for quantification. Only the peptides without modifications were 
taken into consideration in quantitative analysis. 
 
Functional clustering 
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Significantly altered proteins were clustered on the basis of the UniProt 
(http://www.uniprot.org/) and GeneOntology (http://geneontology.org/) databases. The 
proteins showing increased or decreased expression levels were clustered separately in groups 
according to their most relevant cellular functions and roles in synaptic processes (Table 1 
and 2). 
 
Bioinformatic analysis of significant protein changes  
The bioinformatic pathway analysis to uncover the linkage between AD and the CCH 
induced significantly altered cortical synaptic proteins was performed by Elsevier Pathway 
Studio Platform.  
 
Western blot 
Among the mass spectrometry identified CCH induced significant protein changes 
APOE was selected for WB validation as it is known to have a major role in Alzheimer’s and 
cardiovascular diseases. For validation the same samples were used which were utilized in the 
mass spectrometry analysis. Proteins were separated with Tricine-SDS-polyacrylamide gel 
electrophoresis on 10 % polyacrylamide gels and transferred to Hybond-LFP PVDF 
membranes (GE Healthcare). The membranes were blocked with 5 % BSA in Tris-buffered 
saline containing 0.1 % Tween 20 (TBS-T). The membranes were incubated overnight in 
rabbit anti-apolipoprotein E primary antibody (EPR19392) (Abcam, ab183597, 1:500 
dilution) and mouse anti-synaptophysin (SY38) (monoclonal) primary antibody (Abcam, 
ab8049, 1:1500 dilution) dissolved in TBS-T. Subsequently, the membranes were washed for 
4 x 5 min in TBS-T followed by the incubation with Cy5 and Cy3 CyDye conjugated anti-
rabbit and mouse IgG secondary antibodies (1:2,500 dilution, GE Healthcare). After the 
washing steps in TBS-T and later in TBS the bands were visualized using a Typhoon TRIO+ 
11	
	
scanner. Fluorescence intensities were quantified using the ImageQuant TL software. The 
densitometry data of protein band intensities were analyzed with Image J software (NIH, 
Bethesda). Densitometric values of the APOE protein bands were normalized to the average 
densities of the synaptophysin (SYP) in the same sample. Differences between CCH and 
control synaptosome samples were statistically analyzed using independent Student’s t-test.  
 
Results 
Magnetic Resonance Angiography 
Magnetic resonance angiography studies show that the blood flow in the carotis 
arteries were successfully blocked bilaterally in all CCH animals while it remained unaffected 
in the sham operated control rats (Fig. 1). The thickening of vertebro-basilar arteries was also 
observed in each CCH animal due to the BCCAO.  
 
Figure 1. Magnetic resonance angiography (MRA) of sham operated control (above) and 
chronic cerebral hypoperfusion (CCH) rat brain (below). Coronal (A), horizontal (B) and 
sagittal (C) views are shown at appropriate levels. Arteries with blood flow appear white in 
12	
	
the images. Successful occlusion of common carotid arteries (CC) and thickening of the	
vertebro-basilar artery (BA) are visible in CCH rats. 
 
Validation of the purity of the synaptosome preparation with electron microscope 
Electron microscopic analysis revealed that the samples consist of synaptosomes 
containing characteristic pre- and postsynaptic elements. Presynaptic endings contain synaptic 
vesicles and mitochondria. Postsynaptic elements were attached to most of the sealed 
presynaptic terminals. Nucleus or cell body related compartment (lysosomes and Golgi 
apparatus) were not present in the samples suggesting the purity and enrichment of the 
synaptosome preparation (Fig. 2). 
 
Figure 2. Electron microscopic images of the synaptosome preparations. The images show 
synaptic vesicle and mitochondria containing sealed presynaptic terminals and postsynaptic 
regions attached to postsynaptic densities. Synaptic endings fill the majority of the 
preparations. *: synaptic mitochondria, arrowheads show synaptic vesicles. Scale bar: 1µm 
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Functional clusters of altered proteins  
In the present study, we identified (with at least 3 peptides) 23 proteins with 
significantly increased (Table 1) and 23 proteins with decreased (Table 2) expression level 
by more than ±1.3-fold change in CCH rats compared to sham operated control animals (t-
test, P < 0.05). Fold changes of the altered proteins were in the range of -1.73 to +1.55. To 
graphically represent the significance and magnitude of protein changes, volcano plot – 
log10(P-value) vs. log2(fold change of hypoperfusion / control group) – was constructed. 
Points above the non-axial horizontal line represent proteins with significantly different 
abundances (P < 0.05). Points to the left of the left non-axial vertical line indicate protein fold 
changes of hypoperfusion / control less than −1.3, while points to the right of the right non-
axial vertical line label protein fold changes of hypoperfusion / control greater than +1.3 (Fig. 
3). 
The proteins showing increased expression levels participate in a variety of metabolic 
processes, including protein biosynthesis and folding (n=6); ubiquitin-mediated degradation 
(n=4); lipid metabolism (n=4); GABA-shunt (n=3); ion transport and homeostasis (n=2); 
MAPK signalling pathway (n=2); mitochondrial transport (n=1) and nucleotide metabolism 
(n=1) based on GeneOntology database. Expressions of protein biosynthesis and folding 
related proteins changed to the greatest extent (Table 1).  
The proteins with decreased expression level after CCH participate in a variety of 
synaptic processes including synaptic vesicle cycle (n=5); synaptic assembly (n=3); 
GABAerg neurotransmission (n=3); ion transport and homeostasis (n=4); neurogenesis (n=3); 
cell adhesion (n=3); complement regulation (n=1) and mitochondrial transport (n=1). 
Expressions of synapse assembly and neurotransmission related proteins decreased to the 
greatest extent. (Table 2). 
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Figure 3. Volcano plot illustrates magnitude and significance of the protein comparisons 
between the hypoperfusion and control groups. The −log10 (P value) is plotted against the 
log2 (fold change: hypoperfusion / control group). The non-axial vertical lines denote ±1.3-
fold change while the non-axial horizontal line denotes P = 0.05 significance threshold (prior 
to logarithmic transformation). Significantly altered proteins with more than ±1.3-fold change 
are highlighted with gene names. 
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Table 1. 
Gene Protein	name AR p-value PN SC% Localisation	 Synaptic	function
Protein	biosynthesis	and	folding	
GARS Glycine--tRNA	ligase	 1.55 0.002 8 21.8 cp,	ax,	mit dendritic	and	axonal	terminal	
arborization	(1)
HNRNPK Heterogeneous	nuclear	ribonucleoprotein	K	 1.53 0.030 10 34.1 cp,	syn,	mit synaptic	transmission,	spine	
development	(2)
NIT1 Nitrilase	homolog	1 1.41 0.016 6 36.0 mit,	cp apoptosis	(GO)
HINT1 Histidine	triad	nucleotide-binding	protein	1 1.37 0.005 5 60.3 cp apoptosis	(GO)
DDX1 ATP-dependent	RNA	helicase	DDX1 1.36 0.001 11 26.8 cp interaction	with	HNRNPK	(3)
PDIA6 Protein	disulfide-isomerase	A6 1.33 0.005 6 20.2 m,	ER,	syn protective	role	agains	hypoxia	and	
misfolded	proteins	(4)
Ubiquitin	mediated	protein	degradation
COPS2 COP9	signalosome	complex	subunit	2	 1.54 0.004 6 22.1 cp neuron	differentation	(GO)
PSMA1 Proteasome	subunit	alpha	type-1	 1.34 0.005 7 43.3 cp synaptic	elimination	(5)
PSMC3 26S	protease	regulatory	subunit	6A	 1.34 0.004 9 32.8 cp
PSMC4 26S	protease	regulatory	subunit	6B	 1.31 0.035 7 42.3 cp
GABA-shunt
AKR7A2 Aflatoxin	B1	aldehyde	reductase	member	2	 1.41 0.012 5 21.0 cp,	Golgi GABA	degradation,	gamma-
hydroxybutyrate	production	(7)
BCAT1 Branched-chain-amino-acid	
aminotransferase,	cytosolic	
1.41 0.012 10 47.4 cp glutamate-GABA	metabolism	(8)
PNPO Pyridoxine-5-phosphate	oxidase 1.40 0.004 3 16.1 cp Glutamate	and	GABA	synthesis	(9)
Lipid	metabolism
PAFAH1B2 Platelet-activating	factor	acetylhydrolase	IB	
subunit	beta	
1.45 0.016 8 68.6 cp
brain	development,	neuronal	migration	
(10)
APOE Apolipoprotein	E	 1.33 0.034 10 41.0 secr neuroregeneration	under	
hypoperfusion,	axonal	growth	(11)
ME1 NADP-dependent	malic	enzyme	 1.34 0.019 14 44.4 mit,	cp glutathion	metabolism,	pyruvate	
recycling	pathway	(15)
GPD1 Glycerol-3-phosphate	dehydrogenase	
[NAD(+)],	cytoplasmic	
1.32 0.036 12 57.0 cp,	mit
connection	between	carbohydrate	and	
lipid	metabolism	(GO)
MAPK	signaling	pathway
MAP2K1 Dual	specificity	mitogen-activated	protein	
kinase	kinase	1	
1.37 0.007 14 58.0 m,	cp
neuron	differentiation	and	projection	
(GO)
PEA15 Astrocytic	phosphoprotein	PEA-15	 1.32 0.014 5 44.6 cp apoptosis	(GO)
Ion	transport	and	homeostasis
TF Serotransferrin	 1.48 0.009 16 29.5 cp,	m,	secr apoptosis,	hypoxia,	ferric	ion	transport	
(GO)
CALB2 Calretinin	 1.46 0.013 9 42.1 syn,	cp synaptic	transmission,	LTP,	calcium	ion	
binding	(16)
Nucleotide	metabolism
HPRT1 Hypoxanthine-guanine	
phosphoribosyltransferase
1.50 0.010 8 45.9 cp brain	development	(GO)
Mitochondrial	transport
CRYM Ketimine	reductase	mu-crystallin	 1.36 0.007 10 60.7 cp regulation	of	the	free	intracellular	
concentration	of	triiodothyronine	(GO)
ATP-dependent	degradation	of	
ubiquitinated	proteins	(6)
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Table 2. 
Protein	ID Protein	name AR p-value PN SC% Localisation	 Synaptic	function
Synaptic	vesicle	cycle
VAMP1 Vesicle-associated	membrane	protein	1 -1.73 0.016 3 33.9 ves,	syn SNARE	assembly,	vesicle	targeting	and	
fusion	(GO)
SNAP25 Synaptosomal-associated	protein	25	 -1.39 0.025 16 68.4 ves,	pre vesicle	docking	and	fusion,	
neurotransmitter	release	(GO)
STX1B Syntaxin-1B	 -1.31 0.005 17 59.4 ves,	pre vesicle	docking	(GO)
AAK1 AP2-associated	protein	kinase	1	 -1.31 0.001 21 41.8 pre,	m synaptic	vesicle	recycling,	receptor-
mediated	endocytosis	(GO)
SCAMP1 Secretory	carrier-associated	membrane	
protein	1
-1.38 0.021 5 26.0 ves,	Golgi,	m protein	transport,	endocytosis	(GO)
Ion	transport	and	homeostasis
ATP2B1 Plasma	membrane	calcium-transporting	
ATPase	1	
-1.35 0.002 43 42.1
m,	ER,	Golgi,	
syn
ATP	hydrolysis	coupled	calcium	ion	
transport	(GO)
ATP1A2 Sodium/potassium-transporting	ATPase	
subunit	alpha-2	
-1.38 0.009 50 52.1 m,	syn,	cp
ATP1A1 Sodium/potassium-transporting	ATPase	
subunit	alpha-1	
-1.35 0.002 50 52.3 m
ATP1A3 Sodium/potassium-transporting	ATPase	subunit	alpha-3 -1.30 0.001 55 62.4 m
Synaptic	assembly
SYNPO Synaptopodin	 -1.45 0.004 16 29.2 syn,	PSD motility	of	dendritic	spines,	actin	filament	bundle	assembly	(GO)
SHANK2 SH3	and	multiple	ankyrin	repeat	domains	
protein	2	
-1.39 0.004 22 30.4 cp,	PSD
SHANK1 SH3	and	multiple	ankyrin	repeat	domains	
protein	1	
-1.37 0.019 17 14.3 cp,	PSD
GABA/glutamatergic	transmission
GABBR2 Gamma-aminobutyric	acid	type	B	receptor	subunit	2 -1.40 0.024 5 9.5 syn,	PSD,	m
G-protein	coupled	GABA	receptor	
activity	(GO)
SLC6A1 Sodium-	and	chloride-dependent	GABA	
transporter	1	
-1.35 0.005 8 22.4 pre,	ves
GABA	reuptake	into	presynaptic	
terminals	(GO)
SLC1A2 Excitatory	amino	acid	transporter	2	 -1.36 0.019 18 35.6 pre released	glutamate	removing	from	the	synaptic	cleft	(GO)
Neurogenesis
RAP1A Ras-related	protein	Rap-1A -1.71 0.010 7 50.0 syn,	cp,	m neuron	projection	development,	vasculogenesis	(GO)
GJA1 Gap	junction	alpha-1	protein	 -1.57 0.013 9 31.2 pm,	ER,	OMM neuron	projection	(GO)
CSPG5 Chondroitin	sulfate	proteoglycan	5	 -1.55 0.003 6 16.1 syn,	ER,	Golgi,	
m
axon	regeneration,	growth	regulation	
(GO)
Cell	adhesion
MOG Myelin-oligodendrocyte	glycoprotein -1.72 0.028 6 25.7 m cell-cell	communication	(GO)
OPCML Opioid-binding	protein/cell	adhesion	
molecule	
-1.42 0.001 11 42.0 m synaptogenesis	(GO)
CD47 Leukocyte	surface	antigen	CD47	 -1.42 0.016 6 19.5 m synaptic	plasticity	(GO)
Complement	regulation
CD59 CD59	glycoprotein	 -1.55 0.000 3 23.0 m
Mitochondrial	transport
TOMM40 Mitochondrial	import	receptor	subunit	
TOM40	homolog	
-1.31 0.039 9 39.3 OMM
import	of	protein	precursors	and	ions	
into	mitochondria	(GO)
organization	of	the	dendritic	spine	and	
synaptic	junction	(GO)
ATP	hydrolysis	coupled	sodium	and	
potassion	ion	transport	(GO)
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Table 1. Significantly increased synaptic proteins in the cerebral cortex of CCH rats assigned 
to functional clusters. The red color gradient is used to show the degree of difference in the 
abundance of each proteins compared to the control group. Abbreviations: AR: average ratio, 
PN: unique peptides number, SC %: sequence coverage percentage. 
(1) - (Chihara et al., 2007), (2) - (Folci et al., 2014), (3) - (Chen et al., 2002), (4) - (Tanaka et 
al., 2000), (5) - (Ding and Shen, 2008), (6) - (Na et al., 2012), (7) - (Lyon et al., 2007), (8) - 
(Sweatt et al., 2004), (9) - (Bahn et al., 2002), (10) - (Manya et al., 1998), (11) - (Kamada et 
al., 2003), (12) - (McKenna et al., 2000), (13) - (Christel et al., 2012), (GO) – According to 
Gene Ontology database. 
 
Table 2. Significantly decreased synaptic proteins in the cerebral cortex of CCH rats assigned 
to functional clusters. The blue color gradient is used to show the degree of differential 
decreasing abundances of CCH proteins, compared to sham operated rats. Abbreviations: AR: 
average ratio, PN: unique peptides number, SC %: sequence coverage percentage. (GO) – 
According to Gene Ontology database. 
 
Western blot 
WB analysis was performed for APOE in the synaptosome fraction of cerebral cortex 
(Fig. 4). The protein expression of APOE (2.32 ± 0.78) showed significant increasing level in 
the CCH synapse compared to the synapse from the sham operated control rats (p < 0.05). 
Thus, the WB results of APOE protein confirmed the LC-MS/MS data.  
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Figure 4. Validation of the increased expression of APOE in synapse.  Immunopositive bands 
are shown at 36 kDa for APOE, and 38 kDa for SYP loading control. Densitometric analysis 
was performed for APOE (n=6). The expression of APOE was significantly increased in the 
CCH synapse compared to the synapse from the sham operated control rats (*: p < 0.05). 
Error bars indicate s.e.m. 
 
Discussion 
Angiography of rats in our study represents a thorough control of the occlusion 
procedure. Indeed, blood supply by the carotid arteries was blocked in all animals. Blood 
supply to the brain by other routes including the visibly thickened vertebro-basilar artery 
compatible with the progressive process of vascular remodelling (Soria et al., 2013). Our 
results indicate that these adaptations are accompanied by alteration of the synaptic protein 
content. The electron microscopic imaging demonstrated that our synaptosome preparation 
contained sealed presynaptic terminals and postsynaptic vacuoles with intact synaptic 
specialization suggesting that the altered proteins are located in these compartments. 
Validation of APOE level was done by Western blotting, which indeed demonstrated an 
increased level of the protein following CCH. 
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 The altered proteins belong to several functional categories. It is noteworthy that 
proteins belonging to the same functional category all increased or decreased their levels in 
CCH animals. This allows interpretation of changes of the particular functional processes in 
the synapse, rather than only individual proteins. Reduced synaptic vesicle cycle, synaptic 
assembly and ion transport, as well as the increased protein and lipid metabolism suggest a 
number of possible mechanisms of this transition (Fig. 5). 
 
 
Figure 5. Connections of significantly altered synaptic proteins to CCH induced main 
neuropathological alterations and diseases. Red or blue highlights indicate synaptic proteins 
increased or decreased by CCH. Green or red arrows indicate the positive or negative 
regulation between the proteins. 
 
Chronic cerebral hypoperfusion effects on GABAergic / glutamatergic synaptic 
communication  
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A number of synaptic transmission related proteins showed decreased level in CCH 
rats. They participate both in the release and reuptake of amino acid neurotransmitters. 
Among them three GABAergic / glutamatergic transmission related proteins showed 
decreased protein level: Excitatory amino acid transporter 2 (SLC1A2), Sodium- and 
chloride-dependent GABA transporter 1 (SLC6A1) and Gamma-aminobutyric acid type B 
receptor subunit 2 (GABABR2). According to published electron microscopic studies, 
SLC1A2 is mainly present in astrocytic soma and processes surrounding capillaries and axon 
terminals mainly around glutamatergic synapses, consistent with its role in facilitating 
glutamate reuptake and limiting glutamate spillover (Roberts et al., 2014). SLC6A1 
immunoreactivity is mainly present in axon terminals of symmetrical synapses in the cortex, 
suited for GABA recycling in the presynaptic terminals following a release event, which is 
essential to sustain GABAergic synaptic transmission (Scimemi, 2014). Metabotropic GABA 
receptors are coupled to second-messenger systems through G-proteins and mediate slow and 
prolonged inhibitory effects (Misgeld et al., 1995). Electron microscopic studies showed that 
GABABR2 is more abundant on postsynaptic than presynaptic side with a dominant 
extrasynaptic membrane localization. Moreover, besides its main GABAergic synaptic 
localization it is also associated with putative glutamatergic synapses suggesting its 
involvement in both GABAergic and glutamatergic neurotransmission (Kulik et al., 2003). 
Consistent with our results, GABABR2 showed decreased cell surface expression in the 
hippocampus of BCCAO rats, which showed significant cognitive impairment (Lu et al., 
2016). 
Baclofen, a GABABR agonist, improved the down-regulation of GABABR2 
expression associated with cognitive impairment (Lu et al., 2016) and special working 
memory impairment (Luo et al., 2016), while also reversed neuronal damage with autophagy 
regulation under chronic cerebral hypoperfusion (Liu et al., 2015). Similar to our synaptic 
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results, AP2-associated protein kinase 1 (AAK1) expression was significantly reduced in the 
hippocampal CA1 region under chronic cerebral hypoperfusion, which could be restored by 
baclofen to the control level (Li et al., 2014) (Fig. 5).  
In the present study, three γ-aminobutiric acid (GABA) shunt related proteins showed 
increasing protein level in the cortical synapse of CCH rats: pyridoxine-5-phosphate oxidase 
(PNPO), branched-chain-amino-acid aminotransferase, cytosolic (BCAT1) and aflatoxin B1 
aldehyde reductase member 2 (ARK72) (or succinic semialdehyde reductase, SSAR) (Fig. 5). 
PNPO catalyzes the oxidation of pyridoxine 5'-phosphate (PNP) into pyridoxal 5'-phosphate 
(PLP) which is an allosteric cofactor of BCAT1 and glutamate decarboxylase (GAD) 
enzymes (Bahn et al., 2002). BCAT1 is localized exclusively in neurons in the adult rat brain 
and catalyzes the reversible transamination of α-ketoglutarate to glutamate while GAD 
catalyzes the decarboxylation of glutamate to GABA (Sweatt et al., 2004). GABA 
degradation has an important role in glutamate- and GABA-erg balance and generates 
succinic semialdehyde (SSA) intermediate via the activation of GABA transaminase (GABA-
T). SSA is normally converted to succinate through the activation of succinic semialdehyde 
dehydrogenase (SSADH). However, upon activation of ARK72, SSA is converted to GHB, as 
an alternative route from the GABA shunt (Picklo et al., 2001).  
 
APOE-mediated synaptic effects of chronic cerebral hypoperfusion 
APOE showed increased level in the synapse of CCH rats. It is indeed known to be 
released from neurons as the consequence of injury or stress (Huang and Mucke, 2012). The 
expression of APOE is significantly increased with AD compared to control brain (Linnertz et 
al., 2014). Furthermore, clinical studies revealed that AD patients have significantly lower 
APOE serum levels but higher cerebrospinal fluid levels compared to healthy (Laske, 2012, 
Martinez-Morillo et al., 2014). APOE4-positive AD individuals are often associated with 
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impaired neurotransmission and elevated β-amyloid levels (Verret et al., 2012). APOE can 
contribute to reduced neurotransmission as it diminishes glutamate receptor function and 
synaptic plasticity (Chen et al., 2010).  
Bioinformatical analysis suggests a central role of APOE in additional synaptic protein 
changes connected to AD (Linnertz et al., 2014) (Fig. 5). APOE, showing significantly 
decreased expression in our paradigm, interacts with mitochondrial import receptor subunit 
TOMM40 homolog (TOMM40), which causes mitochondrial impairment and neurotoxicity 
(Roses et al., 2014). In reverse, polymorphisms in TOMM40 has an effect on the levels of 
APOE in the cerebrospinal fluid of non-demented individuals and in the hippocampus of AD 
patients (Maruszak et al., 2012). Moreover, mutations in TOMM40 gene are important risk 
factors for AD (Dhillon and Fenech, 2014).  
Several pre- (e.g. synaptotagmin, synaptophysin) and postsynaptic proteins including 
synaptopodin (SYNPO), which were downregulated in CCH rats, are also known to be 
downregulated in the brain of AD patients (Reddy et al., 2005). APOE4 gene expression 
inactivates the gene transcription of SYNPO and some other proteins involved in synaptic 
plasticity, synaptic regeneration and remodeling (Xu et al., 2007). SYNPO is an actin-
associated protein playing role in modulating actin-based shape determination and essential to 
the formation of spine apparatuses of neurons, which are involved in synaptic plasticity 
(Yamazaki et al., 2001). The decreased protein level of SYNPO in CCH rats indicates the 
inhibitory effect of CCH on spine formation and synaptic plasticity. APOE genotype 
correlates with synaptosomal-associated protein 25 (SNAP25) depletion in frontotemporal 
lobar degeneration (Connelly et al., 2011), which showed decreased expression in CCH rat 
synapses. Clinical data has already described the reduced level of SNAP25 protein in AD 
suggesting its role in impaired neurotransmission (Furuya et al., 2012), which was also 
strengthened by the fact that single nucleotide polymorphisms are associated with functional 
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MRI parameters in AD (Guerini et al., 2014). SNAP25 increases the surface expression of 
sodium- and chloride-dependent GABA transporter 1 (SLC6A1) (Fan et al., 2006). Moreover, 
SNAP25 and syntaxin 1B (STX1B) are able to interact with each other (Chapman et al., 
1994).  
White matter lesion, one of the main pathological consequence of CCH, is also 
influenced by APOE genotype (Tapiola et al., 2008). Furthermore, CSF levels of APOE 
decreased with increasing degree of white matter lesion (Skoog et al., 1997). 
 
Relationships of chronic cerebral hypoperfusion altered synaptic proteins with cognitive 
impairment and dementia 
Gap junctional communication and Gap junction alpha-1 protein (GJA1) expression is 
affected in cerebral ischemia (Kielian and Esen, 2004) and in different stages of AD (Iacobas 
et al., 2005). Protein kinase C-induced ubiquitylation of GJA1 is partly mediated by the 
mitogen-activated protein kinase pathway (Leithe and Rivedal, 2004). GJA1, and specifically 
its C-terminal domain, is required for optimal LFA-1-mediated Ras-related protein Rap-1A 
(RAP1) activation and spreading (Machtaler et al., 2011). GJA1 directly regulates excitatory 
amino acid transporter 2 (SLC1A2) expression and function and modulates the activity of 
intracellular signal molecules, which in turn leads to its downregulation (Morioka et al., 
2015). SLC1A2 activity is downregulated in AD brain (Boyd-Kimball et al., 2005), and show 
decreased protein level in CCH rats suggesting decreased degree of glutamate removal from 
the synaptic cleft. The decreasing SLC1A2 glutamate transporter and ATP1A2 ATPase are 
part of the same presynaptic macromolecular complex and operate as a functional unit to 
remove released glutamate from the synaptic cleft (Rose et al., 2009). The reduced glutamate 
reuptake in CCH rats suggests decreased GABA synthesis in the presynaptic region under 
hypometabolism. ATP1A1 is the catalytic component of the active enzyme, which catalyzes 
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the hydrolysis of ATP coupled to the exchange of sodium and potassium ions across the 
plasma membrane creating their electrochemical gradient to provide energy for active 
transport of various nutrients. The CCH-induced decreased ATPA1 level indicates 
downregulated synaptic transport during brain hypometabolism. 
Mitogen-activated protein kinase kinase 1 (MAP2K1) has an important role in neuron 
differentiation and projection (Mace et al., 2013). The activity of MAPK signaling is 
markedly increased in AD brains (Rohe et al., 2008). The carbohydrate metabolism-related 
proteins showed increased protein level in CCH rats. Among them, the glucose transport 
regulator astrocytic phosphoprotein PEA-15 (PEA-15) protein may play a protective role in 
AD (Ahn et al., 2014) and is able to bind to MAP2K1. MAP2K1 phosphorylation drives 
cytoplasmic accumulation of heterogeneous nuclear ribonucleoprotein K (HNRPK or 
HNRNPK) synaptic transmission and spine development regulator protein (Habelhah et al., 
2001), whose expression pattern is also correlated with AD progression (Liang et al., 2012).  
ATP-dependent RNA helicase DDX1 (DDX1) could interact with HNRPK which is known to 
be involved in the regulation of transcription, translation, nuclear transport, and signal 
transduction (Chen et al., 2002). 
Serotransferrin (TF) glycosylation (Taniguchi et al., 2008) and aggregation  
(Booyjzsen et al., 2012) may play an important role in the pathophysiology of AD and also 
modulate the homeostasis of full-length APP (Khachaturian, 2008). Secretory carrier-
associated membrane protein 1 (SCAMP1) and AP2-associated protein kinase 1 (AAK1) 
decreases the TF uptake by endocytosis suggesting their role in endocytosis via a mechanism, 
which may involve the recruitment of clathrin coats to the plasma membrane and the trans-
Golgi network (Fernandez-Chacon et al., 2000, Conner and Schmid, 2002). Therefore, a 
decreasing level of SCAMP1 is consistent with increased TF expression in CCH synapse.  
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Chronic cerebral hypoperfusion inflammatory effects 
In the present study, several CCH-induced synaptic protein changes have a strong relationship 
with microglia activation and / or astrocytosis (Fig. 5). Among them, GJA1, SLCA2 and 
Leukocyte surface antigen CD47 (CD47) showed decreased, while APOE, MAP2K1, TF and 
PEA-15 showed increased expression in CCH rats. Interestingly, downregulation or absence 
of GJA1 reduced neuronal loss, capillary fragmentation, astrocytosis and microglia activation 
(Davidson et al., 2013), while reactive astrogliosis increases GJA1 expression (Masaki et al., 
2013, Wallach et al., 2014). Moreover, brain microgliosis and astrogliosis are also affected in 
APOE transgenic mice (Bales et al., 1999) and the absence of APOE dramatically reduced 
amyloid deposition and the resulting astrogliosis and microgliosis (Ophir et al., 2003). APOE 
co-localizes with β-amyloid in basement membrane drainage pathways in the walls of 
arteries. Furthermore, the attachment of ApoE4/β-amyloid complexes to basement membrane 
laminin is significantly weaker than ApoE3/β-amyloid complexes (Zekonyte et al., 2016). 
Several previous reports suggest the hypothesis that impaired APOE4 function modulates β-
amyloid induced effects on inflammatory receptor signaling, including amplification of 
detrimental (toll-like receptor 4-p38α) and suppression of beneficial (IL-4R-nuclear receptor) 
pathways (Tai et al., 2015). 
 
Conclusion 
Cerebrovascular pathology is a major risk factor for cognitive dysfunction in the 
elderly, both on its own, and as a co-morbid pathology (Murphy et al., 2016). CCH is 
associated with altered levels of a number of synaptic proteins in the cerebral cortex. Synaptic 
metabolism and GABA-shunt related proteins are the major functional classes of proteins 
with increased expression, while neurotransmission and synaptic assembly related proteins 
showed the largest decreased protein levels. Bioinformatical analyses of the CCH-altered 
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proteins suggest an important role of APOE in mediating synaptic effect of CCH. APOE 
showed an increasing synaptic level under CCH, which was also confirmed with WB. Our 
identified synaptic protein changes preceding the onset of AD in the CCH model suggest their 
potential role in the progression of AD.  
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